Investors & Media

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

November 4, 2026

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

November 2, 2026

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

October 28, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

September 1, 2026

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

August 6, 2026

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

July 30, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 27, 2026

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

May 20, 2026

Relay Therapeutics Announces Proposed Public Offering of Common Stock

May 19, 2026

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

May 19, 2026

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

May 5, 2026

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

April 29, 2026

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

April 27, 2026

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

April 2, 2026

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

March 16, 2026

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

February 26, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

February 23, 2026

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

February 19, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

February 3, 2026